跳至主要内容
临床试验/EUCTR2014-005519-18-DE
EUCTR2014-005519-18-DE进行中(未招募)1 期

Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Ointment (Test) vs. Diprogenta(R) Ointment (Reference) vs. Vehicle in patients with bacterial infected eczema

Dermapharm AG0 个研究点目标入组 400 人开始时间: 2015年10月28日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Dermapharm AG
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) Women and men = 18 years of age
  • 2) Written consent to study participation after patient information by the investigator
  • 3) Diagnosis of bacterial infected eczema based on clinical symptoms in a treatment area between 5 and 25 cm2
  • 4) At least moderately severe clinical picture, i.e. patients must have a SIRS score = 8. The SIRS (Skin Infection Rating Scale) score is defined as the sum score of the 7 clinical parameters exudate/pus, crusting, erythema, tissue warmth, tissue oedema, itching and pain (each symptom assessed on a scale ranging from 0 (= absent) to 6 (= severe)).
  • 5) Presence of the clinical parameter exudate/pus” (i.e. score = 1)
  • 6) For women of childbearing potential : Application of an efficient contraceptive method (according to CPMP/ICH/286/95) during the whole study
  • 7) For women of childbearing potential: Pregnancy test with negative result prior to study start
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 400
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1) Presence of a bacterial skin infection which, due to general criteria like severity or depth of the infection, cannot be treated adequately with topical antibiotics alone
  • 2) Presence of any of the following skin conditions in the treatment area: viral infections (e.g. herpes simplex, herpes zoster), dermatomycosis, lues or tuberculosis of the skin, inoculation reactions, rosacea or rosacea-like dermatitis
  • 3) Necessity of application of the study medication in the area around the eyes
  • 4) Necessity of application of the study medication in the area around the ears
  • 5) Necessity of application of the study medication near mucous membranes
  • 6) Systemic therapy with antibiotics within the last 4 weeks before study inclusion
  • 7) Systemic therapy with immunosuppressants or corticoids or medication with neuromuscular blocking effect within the last 2 weeks before study inclusion
  • 8) Local treatment in the test area within the last week before study inclusion
  • 9) Known intolerance or hypersensitivity against gentamicin or other aminoglycosids, betamethasone or other glucocorticoids, or any of the other ingredients in the study medications
  • 10) Advanced renal insufficiency
  • 11) Concomitant diseases like e.g. Myasthenia gravis, Parkinson or other neuromuscular disorders
  • 12) Other severe acute or chronic concomitant disease with severe impairment of the general condition
  • 13) Other concomitant diseases which may - taking the present knowledge into account - influence the parameters evaluated in the study in a way that an objective evaluation would be impossible
  • 14) Necessity for a concomitant medication with neuromuscular blocking effect, e.g. benzodiazepines, or other central or peripheral muscle relaxants
  • 15) Other concomitant medication which may - taking the present knowledge into account - influence the methods of measurement used in this study or the resulting data
  • 16) Reasonable doubt concerning the co-operation of the patient
  • 17) Participation in another clinical study within the last 30 days prior to inclusion in this study
  • 18) Participation in this study at an earlier date
  • 19) Women with existing or intended pregnancy or during lactation

研究者

发起方
Dermapharm AG

相似试验

进行中(未招募)
1 期
Clincal study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substance for patients with chronic stable plaque psoriasis
EUCTR2020-004081-19-DEDermapharm AG306
进行中(未招募)
1 期
Clinical study to compare two creams with the active substance gentamicin and betamethason and one cream without active substance for patients with bacterial infected eczema
EUCTR2014-005518-44-DEDermapharm AG400
招募中
1 期
Clinical study to compare two cutaneous ointments with the active substance methylprednisolone aceponate 0.1% and one cutaneous ointment without active substance for patients with atopic dermatitis
CTIS2024-514548-10-01Dermapharm AG330
进行中(未招募)
1 期
Clinical study to compare the therapeutic effects of two creams with the active substances miconazole and fluprednidene and of one cream without active substance for patients with moderate to severely inflamed infection of the skin through yeast fungi.moderate to severely inflamed candidiasis of the skinMedDRA version: 19.0Level: LLTClassification code 10007159Term: Candidiasis of skin and nailsSystem Organ Class: 100000004862
EUCTR2015-005707-92-DEDermapharm AG340
招募中
1 期
Clinical study to compare two cutaneous creams with the active substance methylprednisolone aceponate 0.1% and one cutaneous cream without active substance for patients with atopic dermatitis
CTIS2024-511390-30-00Dermapharm AG330
Clinical study to compare two ointments with the... | 临床试验